Role of IRF2BP2 in Tumor Immune Evasion
IRF2BP2 在肿瘤免疫逃避中的作用
基本信息
- 批准号:10410406
- 负责人:
- 金额:$ 5.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAntitumor ResponseApoptosisAttenuatedAutomobile DrivingCD4 Positive T LymphocytesCell CycleCellsCharacteristicsChildhood Malignant Brain TumorComplexCyclin-Dependent Kinase 5DataDevelopmentEphA5 ReceptorFutureGene ExpressionGenesGeneticGenetic TranscriptionHarvestIRF1 geneITGAM geneImmuneImmune EvasionImmune responseImmunocompetentImmunologic MarkersImmunotherapeutic agentImmunotherapyInflammationInflammatoryIntentionInterferon Type IIInterferonsInterventionInvestigationKnowledgeMaintenanceMalignant NeoplasmsMediatingModelingMusMutationMyeloid CellsPathway interactionsPhenotypePhosphotransferasesPlayProteinsRegulationResistanceResponse ElementsRoleSHH geneSignal PathwaySignal TransductionSiteSubgroupTestingTranscription CoactivatorTranscriptional ActivationTransducersTumor Cell LineTumor EscapeTumor ImmunityTumor-infiltrating immune cellsUp-RegulationWorkanti-tumor immune responsecell typecytokinedriver mutationgenetic corepressorimmune checkpointimmune checkpoint blockadeimmune resistanceimmunogenicityimmunoregulationin vivoknock-downmedulloblastomamouse modelneoantigensneoplastic cellneuropsychiatrynovelnovel therapeuticsprognosticprogrammed cell death ligand 1promoterresponsestemsuccesstumortumor growthtumor microenvironmenttumor progression
项目摘要
PROJECT ABSTRACT
Understanding the tumor microenvironment (TME) and the prognostic relevance of the cells contributing to it is
vital for developing novel treatments for medulloblastoma (MB), the most common malignant pediatric brain
tumor. Immune resistance in a murine model of MB (MM1) is associated with enhanced tumor expression of the
immune checkpoint programmed death ligand-1 (PD-L1) in response to anti-tumor cytokine interferon-gamma
(IFNγ) signaling. Disruption of this pathway via knockdown of cyclin dependent kinase 5 (CDK5), an essential
transducer of the IFNγ signal, leads to an inflammatory TME phenotype and enhanced tumor rejection in vivo.
IFNγ-induced PD-L1 gene expression is thought to be regulated at the promoter level by competition between
the transcriptional activator IRF1 and repressor IRF2. IFNγ-Cdk5 signaling decreases IRF2 expression and is
associated with hypo-phosphorylation of its co-repressor IRF2BP2, driving IRF1-mediated transcriptional
activation.
IRF2BP2 has emerged as a vital transcriptional co-factor in multiple cell types, with roles in the regulation of
apoptosis, cell cycling, and inflammation. However, its function in cancer is poorly defined. We hypothesize that
formation of the IRF2/IRF2BP2 co-repressor normally attenuates PD-L1 transcription, and that inhibition of this
complex by IFNγ-Cdk5 signaling unleashes PD-L1 expression and results in immune evasion. This project aims
to assess the function of the IRF2/IRF2BP2 complex at the PD-L1 promoter level during basal and IFNγ-
stimulated conditions in MB, with complementary studies on how perturbations in this tumor-intrinsic signaling
pathway leads to shifts in the TME composition in vivo. Aim 1 will characterize the role of IRF2BP2 in mediating
the function of interferon-sensitive response elements (ISRE)-containing gene promoters. Aim 2 will assess the
effect of IRF2BP2 on tumor growth and immune infiltration in vivo. Success in this effort will enable an in-depth
understanding of the tumor-intrinsic regulation of immune sensitivities in MB, thereby facilitating rational targeted
immunotherapeutic approach development in the future against MB and possibly other cancers.
项目摘要
了解肿瘤微环境(TME)和促成肿瘤微环境的细胞的预后相关性,
对于开发髓母细胞瘤(MB)的新疗法至关重要,MB是最常见的儿童恶性脑肿瘤
肿瘤MB(MM 1)小鼠模型中的免疫耐药性与增强的肿瘤表达相关,
免疫检查点程序性死亡配体-1(PD-L1)对抗肿瘤细胞因子干扰素-γ应答
(IFNγ)信号传导。通过敲低细胞周期蛋白依赖性激酶5(CDK 5)来破坏该途径,
IFNγ信号的转导子,导致炎性TME表型和体内增强的肿瘤排斥。
IFNγ诱导的PD-L1基因表达被认为是在启动子水平上通过与PD-L1基因之间的竞争来调节的。
转录激活因子IRF 1和阻遏因子IRF 2。IFNγ-Cdk 5信号转导降低IRF 2表达,
与其辅阻遏物IRF 2BP 2的低磷酸化相关,驱动IRF 1介导的转录
activation.
IRF 2BP 2已成为多种细胞类型中重要的转录辅因子,在调节细胞增殖中起作用。
细胞凋亡、细胞周期和炎症。然而,其在癌症中的功能定义不清。我们假设
IRF 2/IRF 2BP 2共阻遏物的形成通常会减弱PD-L1转录,而这种抑制作用
通过IFNγ-Cdk 5信号传导的复合物释放PD-L1表达并导致免疫逃避。该项目旨在
评估IRF 2/IRF 2BP 2复合物在PD-L1启动子水平的功能,
MB中的刺激条件,以及对这种肿瘤内在信号传导中的扰动如何进行补充研究
TME通路导致体内TME组成的变化。目的1将表征IRF 2BP 2在介导
含干扰素敏感反应元件(ISRE)基因启动子的功能。目标2将评估
IRF 2BP 2对体内肿瘤生长和免疫浸润的影响。这一努力的成功将使人们能够深入了解
了解MB中免疫敏感性的肿瘤内在调节,从而促进合理靶向
免疫途径的发展,在未来对MB和可能的其他癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
muta abiff其他文献
muta abiff的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('muta abiff', 18)}}的其他基金
相似海外基金
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
通过间质局部消融免疫疗法增强全身抗肿瘤反应,与转移性胰腺肿瘤的免疫检查点疗法协同作用
- 批准号:
10580071 - 财政年份:2022
- 资助金额:
$ 5.18万 - 项目类别:
Development of new cancer treatment utilizing the enhancement of antitumor response caused by allo reaction
利用同种异体反应增强抗肿瘤反应开发新的癌症治疗方法
- 批准号:
20K17649 - 财政年份:2020
- 资助金额:
$ 5.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of CD4 T cells and APCs in the induction and maintenance of an effective antitumor response
CD4 T 细胞和 APC 在诱导和维持有效抗肿瘤反应中的作用
- 批准号:
nhmrc : 143674 - 财政年份:2001
- 资助金额:
$ 5.18万 - 项目类别:
NHMRC Project Grants
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
- 批准号:
2377164 - 财政年份:1997
- 资助金额:
$ 5.18万 - 项目类别:
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
- 批准号:
2712876 - 财政年份:1997
- 资助金额:
$ 5.18万 - 项目类别:














{{item.name}}会员




